EN
DE
Home
About us
Biofronteras Expertise
Management and supervisory board
Product Pipeline
Clinical trials
Products
Product Portfolio
Investors & Media
Current capital measure
Key stock information
Financial reports
Financial announcements
Shareholder structure
Corporate calendar
Corporate governance
Annual general meeting
SEC reporting
FAQs Delisting BFRA
Presentations & contact
Career
Careers
Contact
Biofrontera
Investors & Media
Financial announcements
Latest News Releases
05/31/2023 11:30
PTA-News: Biofrontera AG: Biofrontera reports results for the first quarter of 2023
05/29/2023 12:05
PTA-News: Biofrontera AG: First quarter conference call to be held on May 31, 2023
05/17/2023 09:20
PTA-News: Biofrontera AG: Biofrontera completes patient recruitment of Ameluz® Phase I trial
04/27/2023 23:20
PTA-News: Biofrontera AG: BIOFRONTERA REPORTS RESULTS FOR THE FISCAL YEAR 2022
01/18/2023 11:50
PTA-News: Biofrontera AG: Start of Phase 3 Clinical Trial in the US for the Treatment of Actinic Keratosis on the Extremities, Neck and Trunk
01/12/2023 11:30
PTA-News: Biofrontera AG: Biofrontera receives notice of allowance for US patent on innovative photodynamic treatment protocol
01/06/2023 08:25
PTA-News: Biofrontera AG: Court Rules 2021 Executive Board and Supervisory Board Resolutions Concerning IPO of Biofrontera Inc. To Be Unlawful
12/19/2022 14:05
PTA-News: Biofrontera AG: Commercial launch of Ameluz® in Finland
12/08/2022 13:55
PTA-News: Biofrontera AG: Biofrontera establishes UK subsidiary to strengthen its sales activities in the country
11/23/2022 15:00
PTA-News: Biofrontera AG: Biofrontera reports on business development in the third quarter and the first nine months of 2022
Financial announcements
Material News
Current & Archive (Related Party Transactions incl.)
Corporate News
Current & Archive
Voting Rights
Notifications
Current & Archive
Directors' Dealings
Current & Archive
